Stoke Therapeutics develops RNA-based therapies aimed at restoring protein expression to address genetic diseases, focusing on conditions like Dravet syndrome and autosomal dominant optic atrophy (ADOA).

Stoke Therapeutics

Stoke Therapeutics | 12,841 followers on LinkedIn. Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating severe diseases. We are initially focused on diseases of the central nervous system and the eye, with an emphasis on haploinsufficiencies, which are diseases caused by a loss of about half of the normal protein function.

Chief Financial Officer (CFO)

Stephen Tulipano

SVP and Head of Clinical Development Operations

Marissa V.

Vice President Quality Assurance

Samuel Manoranjan

Lynne Weston

Celebrating #Diwali is a beloved tradition at Stoke. As the Festival of Lights, our team looks forward to celebrating together every year with lights, food, and a sense of community. This meaningful holiday symbolizes renewal, unity, and togetherness – all values that resonate deeply within our team. #StokedAboutStoke

We’re proud to support Biomedical Science Careers Program (BSCP) ’s Evening of Hope, an event dedicated to advancing opportunities for underrepresented minorities and inspiring future leaders in biomedical sciences. The work of BSCP in fostering diversity and inclusion is critical in shaping the future of healthcare. We’re honored to support their important mission. Together, we can continue to break down barriers and create pathways for the next generation of experts in science and medicine. #BSCP #eveningofhope2024

Today on #SUDEPActionDay2024 , we’re raising awareness about Sudden Unexpected Death in Epilepsy (SUDEP) and the importance of understanding this serious risk. Raising awareness about the risks associated with epilepsy is essential. Taking an active role in discussing, reviewing, and reducing these risks helps ensure that those affected by epilepsy can live safer and healthier lives. We stand with the epilepsy community and support families navigating these challenges. Learn more and get involved: https://lnkd.in/em8nkZy #SUDEP #OurRisksOurRights

I'm elated to share that our manuscript titled “Antisense Oligonucleotide STK-002 Increases OPA1 in Retina and Improves Mitochondrial Function in Autosomal Dominant Optic Atrophy Cells” was recently accepted for publication in Nucleic Acid Therapeutics and is now available online! https://lnkd.in/etXWiw4t This study presents preclinical data that support the progression of STK-002 towards the clinic as the first potential disease-modifying treatment for autosomal dominant optic atrophy (ADOA), an inherited disease that often leads to blindness and currently has no treatment. A heartfelt thank you to my amazing colleagues and mentors at Stoke Therapeutics who contributed their time, expertise, and passion to this project. Your dedication and collaboration were invaluable and made this accomplishment possible. Reflecting on this journey, I’m reminded of how fulfilling and satisfying it is to engage in research that not only pushes the boundaries of knowledge but also holds the potential to make a difference in the lives of patients suffering from severe genetic diseases. It’s a powerful reminder of why we do what we do at Stoke! #oligonucleotide #antisense #RNA #ADOA #OPA1 #biotech

Aditya Venkatesh

Today, Stoke announced highlights from presentations at the 15th European Epilepsy Congress related to the Company’s work to develop the first disease-modifying medicine for #Dravetsyndrome . Learn more in our press release: https://lnkd.in/dxKt8Pbm #ILAE #EEC2024 International League Against Epilepsy

Stoke is pleased to announce the appointment of Eric Olson as Chief Business Officer. Mr. Olson brings two decades of successful corporate business development experience with an emphasis on #rarediseases and #RNA therapeutics https://lnkd.in/eT4Nk7bv

Today we announced upcoming investor conference presentations at H.C. Wainwright & Co., LLC ’s 26th Annual Global Investment Conference and Cantor Fitzgerald ’s 2024 Global Healthcare Conference. Learn more: https://lnkd.in/d8bErxUj #CantorHCC #Biotech #innovation #investment

The Stoke team is heading to the International League Against Epilepsy's 15th European #Epilepsy Congress in Rome! We look forward to sharing encore data from our #Dravetsyndrome clinical program. Learn more about our upcoming presentations: https://lnkd.in/eWNxNQGC #EEC2024 #ILAE

#ICYMI Our co-founder Isabel Aznarez discussed how her early research in human genetics inspired her and put her on the path to dedicate her life to science. Learn more about Isabel’s background, what led her to start Stoke, and the work her team is doing to target the underlying cause of severe diseases with a unique RNA-based approach. #StokedAboutStoke #RNA #biotech #innovation BiotechTV , Brad Loncar

Our CEO Edward M. Kaye, MD sat down with Brad Loncar of BiotechTV to discuss why he’s so excited to be leading Stoke in our mission to change the way severe diseases are treated by upregulating protein expression with #RNA -based medicines. #StokedAboutStoke #biotech #leadership

HSTS

Amazon

jQuery CDN

Mobile Optimized

Amazon Oregon Region

Drupal

Adobe Dynamic Tag Management

Verizon

Drupal 10

Akamai EdgeWorkers

Chief Medical Officer

Barry Ticho

Chief Communications Officer

Dawn Kalmar

Edward Kaye

Chief Scientific Officer

Gene Liau

Co-Founder and VP, Head of Discovery Research

Isabel Aznarez

Deputy General Counsel

Jonathan Allan

Healthcare

Kimberly Parkerson

VP Medicinal Chemistry

Robert Goodnow

Chief Regulatory Affairs Officer and SVP, Head of QA

Shamim Ruff

Garry Menzel

Aaron Kantoff

Arthur Levin

CEO & Founder

VP, Biology and Co-Founder

Huw Nash

Founder, COO & CBO

Thomas Leggett

Chief Financial Officer

Adrian Krainer

Co-founder & Director

Stephen J. Tulipano

Sam Hall

Director

Greater Boston Area Companies With More Than 50 Employees

Redmile Group Portfolio Companies

East Coast Female Founded Public Companies

Biotechnology Companies With Less Than $50M in Revenue (Top 10K)

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.

Post-IPO Equity - Stoke Therapeutics

Apple Tree Partners

RTW Investments

Series B - Stoke Therapeutics

Series A - Stoke Therapeutics

Computer and Software Services and Scientific Services

Bedford

Massachusetts

United States

North America

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Stoke Therapeutics files automatic mixed securities shelf

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Stoke Therapeutics GAAP EPS of -$0.46, revenue of $4.83M

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome (NASDAQ:STOK)

A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics

We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth

Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

Hong Kong

Asia

Philippines

India

Ukraine

Europe

HTML5

Office 365

Wordpress

F5 NGINX

Google Maps API

DigiCert

Google Compute Engine

Google Analytics

Vimeo

Google Tag Manager

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

news impact assignment basic	general
public peers	general	Nov 6, 2024 11:17 PM	18270ba0
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 6, 2024 11:17 PM	46585298
crunchbase trigger	general	Nov 6, 2024 11:17 PM	607718ac
crunchbase profile	general	Nov 7, 2024 6:30 PM	ca6633d6
li profile	general	Nov 6, 2024 11:17 PM	7011336c
translate crunchbase fundingrounds	general	Nov 7, 2024 7:12 PM	f3f650c3
peers	general	Nov 6, 2024 11:17 PM	50bccb74
news basic	general	Nov 6, 2024 11:17 PM	9ab911ec
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:STOKETHERAPEUTICS

Stoke Therapeutics

Last Close

11.27

22/11 21:00

Market Cap

691.12M

Beta: -

Volume Today

240.61K

Avg: -